R8404
Rufinamide
≥98% (HPLC), powder
Synonym(s):
1-[(2,6-difluorophenyl)methyl]-1H-1,2,3-Triazole-4-carboxamide
Sign In to View Organizational & Contract Pricing.
Select a Size
About This Item
Empirical Formula (Hill Notation):
C10H8F2N4O
CAS Number:
Molecular Weight:
238.19
NACRES:
NA.77
PubChem Substance ID:
UNSPSC Code:
12352200
MDL number:
InChI key
POGQSBRIGCQNEG-UHFFFAOYSA-N
SMILES string
NC(=O)c1cn(Cc2c(F)cccc2F)nn1
InChI
1S/C10H8F2N4O/c11-7-2-1-3-8(12)6(7)4-16-5-9(10(13)17)14-15-16/h1-3,5H,4H2,(H2,13,17)
assay
≥98% (HPLC)
form
powder
color
white
solubility
DMSO: 9 mg/mL
originator
Novartis
storage temp.
−20°C
Quality Level
Gene Information
Looking for similar products? Visit Product Comparison Guide
Application
Rufinamide has been used to test its analgesic effect on neuropathic pain in spared nerve injury (SNI) model.
Biochem/physiol Actions
Broad-spectrum anticonvulsant.
Rufinamide may elicit inhibition of the sodium channels and block action potential generation. This property makes it an antiepileptic drug for treating epilepsy disorders like Lennox-Gastaut syndrome.
Features and Benefits
This compound was developed by Novartis. To browse the list of other pharma-developed compounds and Approved Drugs/Drug Candidates, click here.
General description
Effective therapy for partial seizures in adults and childhood seizures in Lennox-Gastaut syndrome.
signalword
Warning
hcodes
Hazard Classifications
Carc. 2 - Repr. 2 - STOT SE 3
target_organs
Central nervous system
Storage Class
11 - Combustible Solids
wgk
WGK 3
flash_point_f
Not applicable
flash_point_c
Not applicable
Regulatory Information
新产品
This item has
Choose from one of the most recent versions:
Already Own This Product?
Find documentation for the products that you have recently purchased in the Document Library.
K K Jain
Expert opinion on investigational drugs, 9(4), 829-840 (2000-11-04)
This article evaluates rufinamide, a new anti-epileptic drug (AED) in Phase III development. This review is done against the background of therapeutic challenges of epilepsy, old established AEDs, newly introduced AEDs and AEDs in clinical development. Pharmacological properties of 12
Iolanda Mazzucchelli et al.
Analytical and bioanalytical chemistry, 401(3), 1013-1021 (2011-06-07)
The development of a simple and rapid high-performance liquid chromatography (HPLC) method for the determination of the new antiepileptic drug rufinamide (RFN) in human plasma and saliva is reported. Samples (250 μl) are alkalinized with ammonium hydroxide (pH 9.25) and
Shin Hye Kim et al.
Seizure, 21(4), 288-291 (2012-03-17)
To evaluate the efficacy of rufinamide as an add-on treatment in children and adolescents with Lennox-Gastaut syndrome (LGS). The study was an open-label, observational clinical trial of rufinamide as an add-on treatment in intractable LGS patients. This intent-to-treat trial included
Santiago Arroyo
Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics, 4(1), 155-162 (2007-01-03)
Rufinamide is a triazole derivative structurally unrelated to currently marketed antiepileptic drugs. Rufinamide was profiled for anticonvulsant activity at the National Institutes of Health and showed broad-spectrum anticonvulsant properties at nontoxic doses in animal models. The principal mechanism of action
Heather Ann Wier et al.
Paediatric drugs, 13(2), 97-106 (2011-03-01)
Rufinamide is a triazole derivative with broad-spectrum antiepileptic effects that is unrelated to any antiepileptic drug currently on the market. The European Commission and the US FDA approved rufinamide in 2007 and 2008, respectively, for adjunctive treatment of seizures associated
Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.
Contact Technical Service